.png?#)
Nuvation Bio scores first FDA approval for new lung cancer drug
Nuvation Bio on Wednesday won FDA approval with its first commercialized drug, Ibtrozi, for advanced ROS1-positive non-small cell lung cancer (NSCLC). The approval of Ibtrozi, known generically as taletrectinib, follows the company's purchase of AnHeart ...
Nuvation Bio on Wednesday won FDA approval with its first commercialized drug, Ibtrozi, for advanced ROS1-positive non-small cell lung cancer (NSCLC).
The approval of Ibtrozi, known generically as taletrectinib, follows the company's purchase of AnHeart ...
